Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kaloshi

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 5, 2011
Carboplatin chemotherapy in patients with recurrent high-grade gliomaG Kaloshi, M Petrela
Revue Neurologique|October 10, 2006
[Multiple gliomas: clinical studies and pathophysiological hypothesis]K Auré, F Laigle-Donadey, G Kaloshi, et al.
Neurology|August 4, 2006
Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastomaC Carpentier, F Laigle-Donadey, Y Marie, et al.
Neurology|August 12, 2009
Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebriG Kaloshi, R Guillevin, N Martin-Duverneuil, et al.
Journal of Neuro-Oncology|November 17, 2017
Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kineticsC Izquierdo, A Alentorn, A Idbaih, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 24, 2016
Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic CharacteristicsP Mazzocco, C Barthélémy, G Kaloshi, et al.
Neurology|February 21, 2008
Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebriG Kaloshi, S Everhard, F Laigle-Donadey, et al.
Neurology|November 13, 2009
Supratentorial low-grade gliomas in older patientsG Kaloshi, D Psimaras, K Mokhtari, et al.
Neurology|October 27, 2010
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomasC Houillier, X Wang, G Kaloshi, et al.
Journal of Neuro-Oncology|August 20, 2013
Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapyF Ducray, G Kaloshi, C Houillier, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Oncology (Royal College of Radiologists (Great Britain))|April 5, 2011
Carboplatin chemotherapy in patients with recurrent high-grade gliomaG Kaloshi, M Petrela
Revue Neurologique|October 10, 2006
[Multiple gliomas: clinical studies and pathophysiological hypothesis]K Auré, F Laigle-Donadey, G Kaloshi, et al.
Neurology|August 4, 2006
Polymorphism in Sp1 recognition site of the EGF receptor gene promoter and risk of glioblastomaC Carpentier, F Laigle-Donadey, Y Marie, et al.
Neurology|August 12, 2009
Gray matter involvement predicts chemosensitivity and prognosis in gliomatosis cerebriG Kaloshi, R Guillevin, N Martin-Duverneuil, et al.
Journal of Neuro-Oncology|November 17, 2017
Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kineticsC Izquierdo, A Alentorn, A Idbaih, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 24, 2016
Prediction of Response to Temozolomide in Low-Grade Glioma Patients Based on Tumor Size Dynamics and Genetic CharacteristicsP Mazzocco, C Barthélémy, G Kaloshi, et al.
Neurology|February 21, 2008
Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebriG Kaloshi, S Everhard, F Laigle-Donadey, et al.
Neurology|November 13, 2009
Supratentorial low-grade gliomas in older patientsG Kaloshi, D Psimaras, K Mokhtari, et al.
Neurology|October 27, 2010
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomasC Houillier, X Wang, G Kaloshi, et al.
Journal of Neuro-Oncology|August 20, 2013
Ongoing and prolonged response in adult low-grade gliomas treated with radiotherapyF Ducray, G Kaloshi, C Houillier, et al.
Pageof 2